Asunercept
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) [1][2][3].
Product Specifications
CAS Number
1450882-18-4
Product Name Alternative
APG101; CAN008
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/asunercept.html
Purity
98.13
Solubility
10 mM in DMSO
Smiles
[Asunercept]
Molecular Weight
(84.05 kDa)
References & Citations
[1]Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26 (7) :716-27. |[2]Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100. |[3]Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel) . 2020 Dec 8;12 (12) :3683.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![RACGAP1 Recombinant Rabbit Monoclonal Antibody [JE41-19]](https://cdn.genprice.uk/products/992/68dd1c8c061270361ea81aee/imageurl/ha721687.webp)
HA721687 100 µL
RACGAP1 Recombinant Rabbit Monoclonal Antibody [JE41-19]
Sign In for Pricing
View Details 